Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases

Abstract Patients with moyamoya disease (MMD) or intracranial atherosclerotic disease (ICAD) experience similar cerebral ischaemic events. However, MMD patients show greater angiogenesis and arteriogenesis, which play crucial roles in collateral circulation development to enhance clinical prognosis...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wei Hu, Wan Jiang, Li Ye, Yanghua Tian, Bing Shen, Kai Wang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/1e3bc79669ea4c91a9881d5d47dfcf47
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1e3bc79669ea4c91a9881d5d47dfcf47
record_format dspace
spelling oai:doaj.org-article:1e3bc79669ea4c91a9881d5d47dfcf472021-12-02T15:06:14ZProspective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases10.1038/s41598-017-05664-82045-2322https://doaj.org/article/1e3bc79669ea4c91a9881d5d47dfcf472017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-05664-8https://doaj.org/toc/2045-2322Abstract Patients with moyamoya disease (MMD) or intracranial atherosclerotic disease (ICAD) experience similar cerebral ischaemic events. However, MMD patients show greater angiogenesis and arteriogenesis, which play crucial roles in collateral circulation development to enhance clinical prognosis and outcome. Apelins have been associated with angiogenesis and arteriogenesis. Therefore, the aim of the present study was to determine whether apelin levels were higher in patients with MMD than in patients with ICAD or in healthy controls. We compared plasma apelin levels in 29 patients with MMD, 82 patients with ICAD, and 25 healthy participants. Twelve-hour fasting blood samples were collected and analysed using commercially available kits. Univariate analyses indicated that compared with the ICAD and healthy control groups, the MMD group had higher apelin-12, apelin-13, apelin-36, and nitric oxide levels. Binary logistic regression analyses further showed that the plasma apelin-12 level was substantially higher in MMD patients than in ICAD patients. Patients with MMD were also differentiated from patients with ICAD by their mean ages, with the former being younger. Therefore, the plasma apelin-12 level is a potential diagnostic marker for differentiating MMD and ICAD and may provide a treatment strategy for enhancing collateral circulation development and clinical prognosis and outcome.Wei HuWan JiangLi YeYanghua TianBing ShenKai WangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Wei Hu
Wan Jiang
Li Ye
Yanghua Tian
Bing Shen
Kai Wang
Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases
description Abstract Patients with moyamoya disease (MMD) or intracranial atherosclerotic disease (ICAD) experience similar cerebral ischaemic events. However, MMD patients show greater angiogenesis and arteriogenesis, which play crucial roles in collateral circulation development to enhance clinical prognosis and outcome. Apelins have been associated with angiogenesis and arteriogenesis. Therefore, the aim of the present study was to determine whether apelin levels were higher in patients with MMD than in patients with ICAD or in healthy controls. We compared plasma apelin levels in 29 patients with MMD, 82 patients with ICAD, and 25 healthy participants. Twelve-hour fasting blood samples were collected and analysed using commercially available kits. Univariate analyses indicated that compared with the ICAD and healthy control groups, the MMD group had higher apelin-12, apelin-13, apelin-36, and nitric oxide levels. Binary logistic regression analyses further showed that the plasma apelin-12 level was substantially higher in MMD patients than in ICAD patients. Patients with MMD were also differentiated from patients with ICAD by their mean ages, with the former being younger. Therefore, the plasma apelin-12 level is a potential diagnostic marker for differentiating MMD and ICAD and may provide a treatment strategy for enhancing collateral circulation development and clinical prognosis and outcome.
format article
author Wei Hu
Wan Jiang
Li Ye
Yanghua Tian
Bing Shen
Kai Wang
author_facet Wei Hu
Wan Jiang
Li Ye
Yanghua Tian
Bing Shen
Kai Wang
author_sort Wei Hu
title Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases
title_short Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases
title_full Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases
title_fullStr Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases
title_full_unstemmed Prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases
title_sort prospective evaluation of the diagnostic value of plasma apelin 12 levels for differentiating patients with moyamoya and intracranial atherosclerotic diseases
publisher Nature Portfolio
publishDate 2017
url https://doaj.org/article/1e3bc79669ea4c91a9881d5d47dfcf47
work_keys_str_mv AT weihu prospectiveevaluationofthediagnosticvalueofplasmaapelin12levelsfordifferentiatingpatientswithmoyamoyaandintracranialatheroscleroticdiseases
AT wanjiang prospectiveevaluationofthediagnosticvalueofplasmaapelin12levelsfordifferentiatingpatientswithmoyamoyaandintracranialatheroscleroticdiseases
AT liye prospectiveevaluationofthediagnosticvalueofplasmaapelin12levelsfordifferentiatingpatientswithmoyamoyaandintracranialatheroscleroticdiseases
AT yanghuatian prospectiveevaluationofthediagnosticvalueofplasmaapelin12levelsfordifferentiatingpatientswithmoyamoyaandintracranialatheroscleroticdiseases
AT bingshen prospectiveevaluationofthediagnosticvalueofplasmaapelin12levelsfordifferentiatingpatientswithmoyamoyaandintracranialatheroscleroticdiseases
AT kaiwang prospectiveevaluationofthediagnosticvalueofplasmaapelin12levelsfordifferentiatingpatientswithmoyamoyaandintracranialatheroscleroticdiseases
_version_ 1718388498846711808